(0.31%) 5 115.87 points
(0.31%) 38 359 points
(0.34%) 15 982 points
(-0.88%) $83.11
(5.77%) $2.03
(0.37%) $2 355.90
(0.48%) $27.67
(4.02%) $959.20
(-0.22%) $0.933
(-0.40%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $14.58
発行日: 14 2月 2024 @ 23:30
リターン: 18.07%
前回のシグナル: 2月 13 - 04:52
前回のシグナル:
リターン: 1.02 %
Live Chart Being Loaded With Signals
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors...
Stats | |
---|---|
本日の出来高 | 267 602 |
平均出来高 | 482 846 |
時価総額 | 869.08M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-0.870 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.60 |
ATR14 | $0.0310 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Pons Jaume | Buy | 25 846 | Common Stock |
2024-04-16 | Pons Jaume | Sell | 50 000 | Common Stock |
2024-04-16 | Pons Jaume | Sell | 25 846 | Employee Stock Option (right to buy) |
2024-04-04 | Pons Jaume | Sell | 20 000 | Common Stock |
2024-03-14 | Lettmann Jason | Buy | 4 400 | Common Stock |
INSIDER POWER |
---|
87.34 |
Last 97 transactions |
Buy: 3 594 697 | Sell: 591 760 |
ボリューム 相関
ALX Oncology Holdings 相関
10 最も負の相関 | |
---|---|
NSIT | -0.974 |
OVLY | -0.971 |
SJ | -0.97 |
GXII | -0.967 |
BRIVU | -0.963 |
TETC | -0.961 |
MCAA | -0.961 |
MLTX | -0.961 |
ACVA | -0.961 |
HERA | -0.96 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
ALX Oncology Holdings 相関 - 通貨/商品
ALX Oncology Holdings 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-836 000 (0.00 %) |
EPS: | $-3.74 |
FY | 2023 |
収益: | $0 |
総利益: | $-836 000 (0.00 %) |
EPS: | $-3.74 |
FY | 2022 |
収益: | $0 |
総利益: | $-1.47M (0.00 %) |
EPS: | $-3.03 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-4.52 |
Financial Reports:
No articles found.
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。